Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly’s Zepbound | Global News Avenue

ResMed Stock (RMD) and inspired medical systems (national institute for social policy) fell on Monday as companies making products to treat sleep apnea face new threats from weight-loss drugs.

On Friday, Eli Lilly and Company (Li Lai) report think U.S. Food and Drug Administration (FDA) Approves its obesity drug Zepbound, becoming the first and only drug to treat moderate to severe obstructive sleep apnea in obese adults.

Eli Lilly notes FDA decision made after Phase 3 clinical trial Research shows that Zepbound is about five times more effective than placebo in reducing breathing disturbances in patients who are not using a positive airway pressure (PAP) device to help them sleep.

Carlos Nunez, chief medical officer at ResMed, said the positive effects of the weight-loss drugs give doctors more options for treating sleep apnea, and that the drugs may be used “concomitantly with positive airway pressure (PAP) therapy,” such as the products his company offers.

Despite being down about 4% today, ResMed’s shares are still up about a third this year. Inspire Medical Systems shares fell 1.4% in recent trading and have fallen 9% in 2024. Of the analysts tracked by Visible Alpha, three rate ResMed a “buy,” four rate it a “hold,” seven rate Inspire Medical Systems a “buy” and two “hold.”